NGEN.V - NervGen Pharma Corp.
| Previous Close | 2.2800 |
| Open | 2.2400 |
| Bid | 2.1500 x 0 |
| Ask | 2.2200 x 0 |
| Day's Range | 2.1100 - 2.2400 |
| 52 Week Range | 0.8000 - 3.2500 |
| Volume | 15,400 |
| Avg. Volume | 22,328 |
| Market Cap | 67.549M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3030 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Newsfile
NervGen Pharma to Collaborate on Chronic Spinal Cord Injury Study Sponsored by the State of Ohio
Ohio Department of Higher Education Awards $250,000 Grant To Dr. Jerry Silver, Co-inventor of NervGen's Lead Compound Vancouver, British Columbia--(Newsfile Corp. - June 22, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that Dr. Jerry Silver of Case Western Reserve University ("CWRU") in Cleveland, Ohio, has been awarded a research grant ...
- Newsfile
NervGen Pharma Grants Stock Options
Vancouver, British Columbia--(Newsfile Corp. - June 3, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that the Company has granted 225,000 incentive stock options to Directors, Officers and consultants exercisable at a price of $2.70 per share for a period of five years and that vest equally every three months ...
- Newsfile
NervGen Pharma Reports First Quarter 2020 Results
Phase 1 Clinical Trial Remains on Track for Q4 2020 Vancouver, British Columbia--(Newsfile Corp. - June 1, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today reported its financial results for the first quarter ended March 31, 2020.Paul Brennan, NervGen's President & CEO, stated, "We continue to generate encouraging preclinical data to support ...
- Newsfile
NervGen Pharma Corp. Closes Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - May 20, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, is pleased to announce that it has closed a non-brokered private placement of 1,806,827 units of the Company at a price of CAD$1.25 per unit, for aggregate gross proceeds to the Company of CAD$2,258,534."We appreciate the support ...
- Simply Wall St.
Is NervGen Pharma (CVE:NGEN) In A Good Position To Deliver On Growth Plans?
We can readily understand why investors are attracted to unprofitable companies. For example, although...
- Newsfile
NervGen Pharma Reports 2019 Year End Results
Phase 1 Clinical Study Remains on Track for Q4 2020 Vancouver, British Columbia--(Newsfile Corp. - April 29, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today reported its financial results for the year ended December 31, 2019.Paul Brennan, NervGen's President & CEO, stated, "2019 was an important year for NervGen during which we ...
- Newsfile
NervGen Pharma Provides a Corporate Update in Response to the COVID-19 Pandemic; Announces Upcoming Presentation at Solebury Trout Virtual Investor Conference on April 7th
Phase 1 Clinical Study Remains on Track for Q4 2020 Vancouver, British Columbia--(Newsfile Corp. - April 6, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today provided an update on its business in response to the COVID-19 global crisis.Paul Brennan, NervGen's President & CEO, stated, "In response to the global outbreak of COVID-19, ...
- Newsfile
NervGen Pharma Provides a Development Update on Its Lead Product NVG-291
Vancouver, British Columbia--(Newsfile Corp. - February 26, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today is providing an update to its development plan for its lead program, NVG-291. These changes are the result of a number of factors, including feedback from the United States Food and Drug Administration (the "FDA") on the recently ...
- Newsfile
NervGen Pharma Appoints Bill Adams as Chief Financial Officer
Vancouver, British Columbia--(Newsfile Corp. - February 24, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today announced the appointment of Mr. William (Bill) Adams, CPA, CA, to the position of Chief Financial Officer effective immediately. Mr. Adams replaces Mr. Robert Pilz who will continue to formally support the Company as a consultant. "Bill is ...
- Newsfile
NervGen Pharma Responds to Recent Increase in Market Activity
Vancouver, British Columbia--(Newsfile Corp. - January 13, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, confirms that the Company's management is unaware of any undisclosed information or material change in the Company's operations that would account for the recent increase in market activity.About NervGenNervGen is restoring life's potential by creating innovative solutions for the ...
- Newsfile
NervGen Pharma Appoints Paul Brennan as President & Chief Executive Officer
Lloyd Mackenzie Appointed to the New Position of Chief Operating Officer Vancouver, British Columbia--(Newsfile Corp. - November 27, 2019) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today announced the appointment of Mr. Paul Brennan to the position of President & CEO effective immediately, replacing Dr. Ernest Wong who will continue to formally support the Company ...
- Newsfile
NervGen Pharma Completes Share Issuance to Drug Manufacturing Partner CSBio
Vancouver, British Columbia--(Newsfile Corp. - November 21, 2019) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today announced that, further to its press release dated November 18, 2019, it has issued 1,500,000 common shares (the "Common Share(s)") to its manufacturing partner, CSBio, as partial consideration for an order of NVG-291 that will be used ...
- Newsfile
NervGen Pharma Receives Investment from Drug Manufacturing Partner
CSBio Invests US$1,500,000 as Part of Manufacturing Contract for Clinical Trial Product Vancouver, British Columbia--(Newsfile Corp. - November 18, 2019) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today announced that it has entered into an agreement to issue 1,500,000 common shares at a price of US$1.00 (CA$1.3231 equivalent) per common share on a private ...
- Newsfile
NervGen Pharma Expands Platform into Alzheimer's Disease
NervGen Pharma's NVG-291 Compound on Track to Begin Phase 1 in Q1 2020 Vancouver, British Columbia--(Newsfile Corp. - October 28, 2019) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating novel treatments for nerve damage and neurodegenerative diseases, today announced a research initiative to advance its proprietary therapeutic technology platform, currently in development for spinal cord injury and multiple sclerosis, to generate new treatments for ...
- Newsfile
NervGen Pharma Announces Clinical Development Plan for the Treatment of Nerve Damage and Neurodegenerative Diseases
NervGen Reports Results of Annual General Meeting of Shareholders Vancouver, British Columbia--(Newsfile Corp. - September 6, 2019) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced the clinical development strategy for its compound, NVG-291, in two lead indications: spinal cord injury and multiple sclerosis. The NVG-291 clinical development program is planned as ...
- Simply Wall St.
How Much Of NervGen Pharma Corp. (CVE:NGEN) Do Insiders Own?
Every investor in NervGen Pharma Corp. (CVE:NGEN) should be aware of the most powerful shareholder groups. Insiders...
- CNW Group
Life Science Company Live Investor Presentations Now Available for On-Demand Viewing
Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view presentations NEW YORK , July 15, 2019 /CNW/ - Virtual Investor Conferences, the ...
